Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
120 shown of 2,571 total abstracts
  1. Abstract 98382026-09-01 · 21:45 CT · S100A
    Long-term follow-up of Keytruda 2L for SCLC: KEYNOTE-398
    A. Spira, T. Mok, C. Saura · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  2. Abstract 91942026-09-01 · 18:15 CT · S406
    PACIFIC-2: Imfinzi (durvalumab) neoadjuvant in SCLC
    A. Spira, T. Mok, N. Rizvi · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  3. Abstract 99002026-09-03 · 18:30 CT · Arie Crown Theater
    Real-world effectiveness of Opdivo vs standard of care in NSCLC
    F. Andre, M. Reck, J. Brahmer, et al. · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  4. Abstract 94472026-09-03 · 19:00 CT · S406
    CheckMate-87: Opdivo (nivolumab) 3L+ in NSCLC
    S. Tolaney, F. Andre, L. Paz-Ares, et al. · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  5. Abstract 90882026-09-02 · 19:15 CT · S406
    PACIFIC-243: Imfinzi (durvalumab) 3L+ in SCLC
    N. Rizvi, C. Saura, M. Krop, et al. · Peter MacCallum Cancer Centre
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  6. Abstract 99302026-09-03 · 16:00 CT · Arie Crown Theater
    IMpower-831: Tecentriq (atezolizumab) maintenance in NSCLC
    S. Modi, E. Winer · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  7. Abstract 92812026-09-05 · 13:30 CT · Hall B1
    Quality of life outcomes with Enhertu in patients with NSCLC
    N. Rizvi, T. Mok · University of Chicago
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  8. Abstract 99922026-09-05 · 18:45 CT · Arie Crown Theater
    Quality of life outcomes with Tagrisso in patients with NSCLC
    T. Mok, M.C. Garassino, M. Krop, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  9. Abstract 93512026-09-05 · 20:45 CT · S100A
    KEYNOTE-158: Keytruda (pembrolizumab) maintenance in SCLC
    S. Peters, J. Brahmer · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  10. Abstract 96832026-09-03 · 13:00 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-163 study)
    S. Peters, H. Borghaei, N. Rizvi, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  11. Abstract 92522026-09-02 · 15:45 CT · S406
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-193
    E. Winer, G. Curigliano · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  12. Abstract 94632026-09-05 · 19:00 CT · S406
    Long-term follow-up of Tagrisso 1L for NSCLC: FLAURA-854
    S. Tolaney, S. Peters, P. Schmid, et al. · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  13. Abstract 91602026-09-03 · 13:30 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in NSCLC (the CheckMate-321 study)
    F. Andre, S. Peters, M. Krop · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  14. Abstract 95282026-09-03 · 18:45 CT · S100A
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-98 study)
    R. Herbst, M. Krop, J. Cortes, et al. · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  15. Abstract 90222026-09-01 · 15:45 CT · Arie Crown Theater
    Quality of life outcomes with Tecentriq in patients with NSCLC
    S. Modi, M. Krop · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  16. Abstract 93842026-09-05 · 20:45 CT · Arie Crown Theater
    PACIFIC-802: Imfinzi (durvalumab) maintenance in NSCLC
    J. Brahmer, G. Curigliano, J. Cortes, et al. · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  17. Abstract 96662026-09-04 · 20:00 CT · E450
    Long-term follow-up of Imfinzi adjuvant for SCLC: PACIFIC-66
    H. Rugo, M. Reck · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  18. Abstract 93672026-09-04 · 21:45 CT · Hall B1
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-166
    H. Borghaei, S. Peters · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  19. Abstract 92442026-09-02 · 18:30 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-489 study)
    S. Modi, C. Saura, R. Herbst · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  20. Abstract 93682026-09-05 · 14:30 CT · Arie Crown Theater
    FLAURA-160: Tagrisso (osimertinib) neoadjuvant in NSCLC
    H. Borghaei, M. Reck, F. Andre, et al. · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  21. Abstract 90452026-09-01 · 19:30 CT · S100A
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-851 study)
    T. Mok, C. Robert · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  22. Abstract 96922026-09-01 · 16:00 CT · Hall B1
    Quality of life outcomes with Keytruda in patients with SCLC
    R. Herbst, S. Modi, M. Reck, et al. · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  23. Abstract 95562026-09-02 · 21:30 CT · E450
    Real-world effectiveness of Tagrisso vs standard of care in NSCLC
    M.C. Garassino, R. Herbst · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  24. Abstract 94722026-09-05 · 13:30 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-301 study)
    A. Spira, M. Krop, E. Winer, et al. · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  25. Abstract 99952026-09-05 · 20:00 CT · S406
    Real-world effectiveness of Tecentriq vs standard of care in NSCLC
    S. Antonia, M.C. Garassino · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  26. Abstract 90652026-09-02 · 20:15 CT · S100A
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-742
    S. Peters, J. Cortes, M. Reck · University of Chicago
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  27. Abstract 93272026-09-01 · 14:45 CT · E450
    Long-term follow-up of Imfinzi adjuvant for NSCLC: PACIFIC-860
    L. Paz-Ares, J. Cortes, J. Brahmer, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  28. Abstract 99342026-09-05 · 21:00 CT · S406
    Quality of life outcomes with Opdivo in patients with NSCLC
    M.C. Garassino, S. Antonia, J. Brahmer, et al. · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  29. Abstract 93932026-09-04 · 15:15 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-430
    L. Paz-Ares, C. Saura, H. Borghaei, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  30. Abstract 94132026-09-05 · 13:00 CT · S406
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    S. Modi, E. Winer · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  31. Abstract 94242026-09-02 · 21:45 CT · S406
    KEYNOTE-938: Keytruda (pembrolizumab) neoadjuvant in NSCLC
    L. Paz-Ares, N. Rizvi, T. Mok, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  32. Abstract 97572026-09-01 · 21:00 CT · S406
    Keytruda plus chemotherapy in previously untreated SCLC: updated analysis from KEYNOTE-945
    G. Curigliano, H. Borghaei, S. Antonia · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  33. Abstract 92612026-09-03 · 15:00 CT · S100A
    FLAURA-46: Tagrisso (osimertinib) 3L+ in NSCLC
    F. Andre, M. Reck, C. Robert, et al. · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  34. Abstract 91792026-09-05 · 18:30 CT · Hall B1
    Long-term follow-up of Tecentriq 1L for NSCLC: IMpower-396
    S. Peters, H. Borghaei, J. Brahmer, et al. · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  35. Abstract 90522026-09-03 · 13:15 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-867
    G. Curigliano, T. Mok, S. Antonia, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  36. Abstract 96682026-09-01 · 21:30 CT · Hall B1
    PACIFIC-178: Imfinzi (durvalumab) 1L in NSCLC
    H. Borghaei, M.C. Garassino, S. Peters, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  37. Abstract 97732026-09-03 · 15:00 CT · Hall B1
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-679
    E. Winer, J. Cortes, H. Rugo, et al. · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  38. Abstract 97152026-09-05 · 13:00 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-601
    S. Antonia, T. Mok · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  39. Abstract 97532026-09-02 · 18:15 CT · Arie Crown Theater
    KEYNOTE-201: Keytruda (pembrolizumab) maintenance in NSCLC
    C. Robert, H. Rugo · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  40. Abstract 96902026-09-03 · 16:00 CT · Arie Crown Theater
    Real-world effectiveness of Imfinzi vs standard of care in SCLC
    L. Paz-Ares, J. Brahmer, N. Rizvi · Princess Margaret Cancer Centre
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  41. Abstract 99972026-09-05 · 19:30 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-854 study)
    G. Curigliano, L. Paz-Ares, H. Borghaei, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  42. Abstract 99082026-09-01 · 20:00 CT · S100A
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-551
    J. Cortes, T. Mok · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  43. Abstract 92672026-09-05 · 19:15 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-296
    E. Winer, S. Peters · University of Chicago
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  44. Abstract 97282026-09-04 · 19:30 CT · Hall B1
    PACIFIC-258: Imfinzi (durvalumab) adjuvant in SCLC
    H. Rugo, F. Andre, N. Rizvi · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  45. Abstract 94742026-09-02 · 15:00 CT · S100A
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-275
    S. Tolaney, P. Schmid, S. Peters, et al. · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  46. Abstract 95952026-09-02 · 19:30 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-520
    J. Cortes, G. Curigliano · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  47. Abstract 99312026-09-02 · 19:15 CT · S100A
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-54
    S. Modi, L. Paz-Ares, G. Curigliano, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  48. Abstract 91672026-09-03 · 20:45 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-437 study)
    S. Antonia, M. Krop, G. Curigliano · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  49. Abstract 91812026-09-03 · 19:45 CT · Hall B1
    Long-term follow-up of Opdivo 2L for NSCLC: CheckMate-290
    P. Schmid, C. Saura · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  50. Abstract 94962026-09-04 · 15:00 CT · S406
    DESTINY-Breast-765: Enhertu (trastuzumab deruxtecan) maintenance in NSCLC
    G. Curigliano, M.C. Garassino, S. Peters, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  51. Abstract 93702026-09-02 · 18:00 CT · E450
    Long-term follow-up of Opdivo neoadjuvant for NSCLC: CheckMate-446
    H. Borghaei, S. Antonia, A. Spira, et al. · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  52. Abstract 92702026-09-02 · 18:30 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-134 study)
    S. Peters, G. Curigliano, T. Mok · Peter MacCallum Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  53. Abstract 92972026-09-02 · 21:00 CT · S406
    FLAURA-510: Tagrisso (osimertinib) adjuvant in NSCLC
    A. Spira, H. Borghaei, E. Winer, et al. · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  54. Abstract 99402026-09-02 · 18:45 CT · Hall B1
    PACIFIC-781: Imfinzi (durvalumab) adjuvant in NSCLC
    M.C. Garassino, F. Andre · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  55. Abstract 97782026-09-04 · 19:15 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-472
    L. Paz-Ares, S. Peters, M. Reck, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  56. Abstract 92532026-09-04 · 14:45 CT · E450
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-66 study)
    A. Spira, M.C. Garassino · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  57. Abstract 95402026-09-01 · 21:00 CT · S100A
    Long-term follow-up of Tecentriq 1L for NSCLC: IMpower-960
    G. Curigliano, S. Antonia · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  58. Abstract 96302026-09-04 · 13:15 CT · S100A
    CheckMate-564: Opdivo (nivolumab) 2L in NSCLC
    T. Mok, L. Paz-Ares, N. Rizvi · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  59. Abstract 93612026-09-04 · 15:45 CT · E450
    FLAURA-374: Tagrisso (osimertinib) 3L+ in NSCLC
    S. Peters, N. Rizvi · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  60. Abstract 92022026-09-05 · 20:45 CT · Arie Crown Theater
    Long-term follow-up of Enhertu 1L for NSCLC: DESTINY-Breast-796
    T. Mok, N. Rizvi, S. Antonia, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  61. Abstract 96082026-09-04 · 14:45 CT · S100A
    Real-world effectiveness of Keytruda vs standard of care in NSCLC
    M.C. Garassino, A. Spira, S. Tolaney, et al. · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  62. Abstract 90642026-09-01 · 14:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-541 study)
    J. Cortes, M.C. Garassino, S. Peters, et al. · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  63. Abstract 99222026-09-04 · 19:30 CT · S100A
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-541 study)
    M. Reck, F. Andre, M.C. Garassino · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  64. Abstract 93042026-09-05 · 19:30 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-278
    H. Rugo, M.C. Garassino, M. Krop · Mayo Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  65. Abstract 92342026-09-04 · 18:45 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-307 study)
    E. Winer, G. Curigliano · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  66. Abstract 98222026-09-01 · 14:30 CT · Hall B1
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-865 study)
    E. Winer, P. Schmid · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  67. Abstract 97682026-09-04 · 20:30 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-521 study)
    N. Rizvi, S. Modi, R. Herbst, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  68. Abstract 94062026-09-03 · 14:15 CT · S406
    Opdivo plus chemotherapy in previously untreated NSCLC: updated analysis from CheckMate-41
    M. Reck, E. Winer · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  69. Abstract 95042026-09-01 · 15:15 CT · S406
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-765 study)
    M. Krop, S. Modi, J. Brahmer, et al. · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  70. Abstract 93092026-09-01 · 13:30 CT · E450
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-71 study)
    L. Paz-Ares, S. Antonia, M. Krop, et al. · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  71. Abstract 99412026-09-01 · 16:15 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-482
    C. Robert, M. Krop, J. Cortes · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  72. Abstract 93842026-09-01 · 18:45 CT · Hall B1
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-233 study)
    R. Herbst, S. Modi, A. Spira, et al. · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  73. Abstract 93312026-09-01 · 14:45 CT · E450
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-190 study)
    M. Krop, M.C. Garassino · Chinese University of Hong Kong
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  74. Abstract 92012026-09-04 · 13:30 CT · S100A
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-543
    E. Winer, F. Andre, P. Schmid, et al. · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  75. Abstract 97282026-09-01 · 13:30 CT · E450
    FLAURA-421: Tagrisso (osimertinib) adjuvant in NSCLC
    E. Winer, C. Saura · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  76. Abstract 97562026-09-04 · 13:30 CT · E450
    PACIFIC-814: Imfinzi (durvalumab) 3L+ in SCLC
    P. Schmid, N. Rizvi · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  77. Abstract 95482026-09-04 · 13:45 CT · S100A
    Biomarker subgroup analysis of Imfinzi in NSCLC (the PACIFIC-608 study)
    A. Spira, L. Paz-Ares, N. Rizvi, et al. · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  78. Abstract 97002026-09-05 · 16:00 CT · S406
    Long-term follow-up of Keytruda adjuvant for SCLC: KEYNOTE-951
    C. Saura, M. Reck · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  79. Abstract 90092026-09-05 · 16:30 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-877
    N. Rizvi, M. Krop · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  80. Abstract 93232026-09-01 · 14:00 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-588
    E. Winer, L. Paz-Ares, S. Tolaney, et al. · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  81. Abstract 90382026-09-01 · 20:00 CT · Hall B1
    Long-term follow-up of Enhertu adjuvant for NSCLC: DESTINY-Breast-259
    J. Cortes, S. Tolaney, G. Curigliano, et al. · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  82. Abstract 92532026-09-02 · 16:15 CT · S100A
    Long-term follow-up of Enhertu 1L for NSCLC: DESTINY-Breast-997
    E. Winer, S. Antonia, M. Krop, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  83. Abstract 90042026-09-05 · 15:15 CT · Hall B1
    Long-term follow-up of Keytruda adjuvant for NSCLC: KEYNOTE-33
    M.C. Garassino, M. Reck, C. Robert, et al. · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  84. Abstract 94922026-09-03 · 20:30 CT · Hall B1
    Imfinzi plus chemotherapy in previously untreated SCLC: updated analysis from PACIFIC-102
    S. Antonia, J. Brahmer, T. Mok · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  85. Abstract 97452026-09-04 · 13:00 CT · S406
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-687
    C. Robert, N. Rizvi, M. Krop, et al. · Johns Hopkins Kimmel Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  86. Abstract 93952026-09-03 · 19:45 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-249
    S. Antonia, M. Krop · Stanford Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  87. Abstract 93612026-09-03 · 18:45 CT · S100A
    Long-term follow-up of Enhertu neoadjuvant for NSCLC: DESTINY-Breast-833
    C. Saura, P. Schmid, M.C. Garassino, et al. · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  88. Abstract 98112026-09-04 · 19:30 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-730 study)
    H. Rugo, M.C. Garassino, J. Brahmer, et al. · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  89. Abstract 92072026-09-05 · 14:30 CT · Hall B1
    Real-world effectiveness of Keytruda vs standard of care in SCLC
    G. Curigliano, C. Robert, N. Rizvi · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  90. Abstract 98192026-09-01 · 14:30 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-272
    N. Rizvi, H. Borghaei, S. Peters, et al. · Princess Margaret Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  91. Abstract 90742026-09-03 · 13:45 CT · E450
    IMpower-819: Tecentriq (atezolizumab) adjuvant in NSCLC
    S. Antonia, F. Andre · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  92. Abstract 98202026-09-05 · 18:15 CT · Arie Crown Theater
    Long-term follow-up of Tagrisso 2L for NSCLC: FLAURA-381
    M.C. Garassino, L. Paz-Ares, S. Peters, et al. · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  93. Abstract 92422026-09-05 · 14:45 CT · S100A
    KEYNOTE-97: Keytruda (pembrolizumab) 3L+ in NSCLC
    R. Herbst, H. Borghaei, T. Mok · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  94. Abstract 90952026-09-03 · 19:30 CT · Arie Crown Theater
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-613 study)
    E. Winer, J. Cortes, P. Schmid, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  95. Abstract 95072026-09-01 · 19:00 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-855
    C. Saura, L. Paz-Ares · Princess Margaret Cancer Centre
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  96. Abstract 93452026-09-04 · 13:30 CT · Hall B1
    Long-term follow-up of Opdivo 3L+ for NSCLC: CheckMate-224
    A. Spira, M.C. Garassino, S. Modi, et al. · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  97. Abstract 97612026-09-04 · 13:15 CT · Hall B1
    Enhertu plus chemotherapy in previously untreated NSCLC: updated analysis from DESTINY-Breast-853
    G. Curigliano, R. Herbst, A. Spira, et al. · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  98. Abstract 95102026-09-03 · 15:30 CT · Hall B1
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-840
    M.C. Garassino, C. Robert, R. Herbst, et al. · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  99. Abstract 91852026-09-02 · 14:15 CT · E450
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-557 study)
    H. Rugo, C. Saura · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  100. Abstract 96402026-09-02 · 13:45 CT · Arie Crown Theater
    Tecentriq plus chemotherapy in previously untreated NSCLC: updated analysis from IMpower-210
    M. Reck, M.C. Garassino, C. Saura · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  101. Abstract 98142026-09-04 · 21:45 CT · S100A
    PACIFIC-176: Imfinzi (durvalumab) adjuvant in SCLC
    H. Rugo, J. Cortes, M. Reck · Karolinska Institute
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  102. Abstract 98592026-09-03 · 13:45 CT · S100A
    FLAURA-464: Tagrisso (osimertinib) 1L in NSCLC
    M. Krop, H. Borghaei, S. Antonia · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  103. Abstract 99502026-09-05 · 14:45 CT · E450
    Long-term follow-up of Imfinzi 3L+ for SCLC: PACIFIC-752
    S. Antonia, R. Herbst, F. Andre · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  104. Abstract 94542026-09-05 · 16:30 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-330
    E. Winer, S. Antonia, S. Peters, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  105. Abstract 90302026-09-05 · 20:30 CT · S100A
    Long-term follow-up of Tagrisso maintenance for NSCLC: FLAURA-776
    F. Andre, A. Spira, S. Antonia · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  106. Abstract 95112026-09-03 · 16:45 CT · S406
    Long-term follow-up of Imfinzi maintenance for NSCLC: PACIFIC-478
    N. Rizvi, L. Paz-Ares, H. Rugo · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  107. Abstract 94692026-09-05 · 19:15 CT · S100A
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-569 study)
    S. Modi, J. Brahmer, S. Antonia, et al. · Royal Marsden Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  108. Abstract 90752026-09-01 · 19:30 CT · S100A
    Long-term follow-up of Tagrisso adjuvant for NSCLC: FLAURA-47
    H. Borghaei, M. Reck, C. Robert · Dana-Farber Cancer Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  109. Abstract 99982026-09-02 · 18:15 CT · Hall B1
    Biomarker subgroup analysis of Enhertu in NSCLC (the DESTINY-Breast-386 study)
    F. Andre, M. Reck · Vall d'Hebron Institute of Oncology
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  110. Abstract 91962026-09-04 · 20:15 CT · Hall B1
    Biomarker subgroup analysis of Keytruda in SCLC (the KEYNOTE-182 study)
    S. Modi, P. Schmid, M.C. Garassino, et al. · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Small Cell📄🖼️🎬
  111. Abstract 90602026-09-01 · 15:00 CT · Hall B1
    Long-term follow-up of Imfinzi neoadjuvant for NSCLC: PACIFIC-72
    F. Andre, C. Robert · Karolinska Institute
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  112. Abstract 98502026-09-03 · 13:45 CT · S406
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-753 study)
    E. Winer, S. Modi · UCSF Helen Diller Family Comprehensive Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  113. Abstract 92002026-09-02 · 19:15 CT · S100A
    Long-term follow-up of Imfinzi maintenance for NSCLC: PACIFIC-415
    S. Tolaney, C. Robert, F. Andre, et al. · Massachusetts General Hospital
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  114. Abstract 90972026-09-05 · 15:45 CT · S100A
    FLAURA-113: Tagrisso (osimertinib) maintenance in NSCLC
    P. Schmid, C. Saura, G. Curigliano · Memorial Sloan Kettering Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  115. Abstract 90602026-09-02 · 19:00 CT · E450
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-403
    S. Antonia, T. Mok, M. Reck, et al. · MD Anderson Cancer Center
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  116. Abstract 95572026-09-05 · 15:30 CT · S100A
    Tagrisso plus chemotherapy in previously untreated NSCLC: updated analysis from FLAURA-801
    N. Rizvi, R. Herbst · University of Chicago
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  117. Abstract 91252026-09-03 · 20:45 CT · Arie Crown Theater
    CheckMate-563: Opdivo (nivolumab) 3L+ in NSCLC
    T. Mok, M.C. Garassino, S. Tolaney, et al. · National Cancer Center Japan
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  118. Abstract 93732026-09-01 · 13:45 CT · S100A
    Biomarker subgroup analysis of Tecentriq in NSCLC (the IMpower-387 study)
    S. Modi, M. Krop, F. Andre, et al. · University of Chicago
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  119. Abstract 93082026-09-02 · 19:30 CT · Hall B1
    Long-term follow-up of Tecentriq neoadjuvant for NSCLC: IMpower-579
    H. Rugo, S. Antonia · Institut Gustave Roussy
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
  120. Abstract 91932026-09-01 · 14:30 CT · Arie Crown Theater
    Imfinzi plus chemotherapy in previously untreated NSCLC: updated analysis from PACIFIC-21
    S. Peters, N. Rizvi, A. Spira · Cleveland Clinic
    Oral Abstract SessionLung Cancer—Non-Small Cell Metastatic📄🖼️🎬
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.